To further confirm whether D1DR and D2DR antagonists attenuate TCI-induced bone cancer pain through inhibiting D1/D2DR heteromers with the subsequent suppression of the activation of the Gq-IP3-PLC pathway, the effects of Gq inhibitor YM254890, IP3 inhibitor 2-APB, and PLC inhibitor U73122 on bone cancer pain were explored. Here, HSPG2 is linked to bone cancer.